10x Genomics (TXG) Financials

$8.16 -0.11 (-1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$8.16 0.00 (0.00%)

As of 07:21 PM Eastern

Annual Income Statements for 10x Genomics

This table shows 10x Genomics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-19	-112	-31	-543	-58	-166	-255	-183
Consolidated Net Income / (Loss)	-19	-112	-31	-543	-58	-166	-255	-183
Net Income / (Loss) Continuing Operations	-19	-112	-31	-543	-58	-166	-255	-183
Total Pre-Tax Income	-19	-112	-31	-534	-54	-162	-249	-178
Total Operating Income	-18	-111	-31	-534	-52	-168	-265	-195
Total Gross Profit	61	118	185	240	416	396	409	414
Total Revenue	71	146	246	299	490	516	619	611
Operating Revenue	71	146	246	299	490	516	619	611
Total Cost of Revenue	11	29	61	58	74	120	209	196
Operating Cost of Revenue	11	29	61	58	74	120	209	196
Total Operating Expenses	79	228	215	775	469	564	675	609
Selling, General & Admin Expense	47	88	131	202	258	298	343	344
Research & Development Expense	32	110	83	571	212	266	331	265
Total Other Income / (Expense), net	-0.37	-1.63	-0.46	1.19	-1.46	5.97	17	17
Interest & Investment Income	0.31	1.02	2.81	1.53	0.21	6.65	17	18
Other Income / (Expense), net	0.14	-0.25	-0.19	1.34	-0.80	-0.20	-0.31	-1.59
Income Tax Expense	0.02	0.09	0.22	8.26	4.51	4.03	6.34	4.93
Basic Earnings per Share	($1.62)	($8.40)	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)
Weighted Average Basic Shares Outstanding	11.59M	13.39M	39.09M	101.15M	110.35M	113.86M	117.17M	120.45M
Diluted Earnings per Share	($1.62)	($8.40)	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)
Weighted Average Diluted Shares Outstanding	11.59M	13.39M	39.09M	101.15M	110.35M	113.86M	117.17M	120.45M
Weighted Average Basic & Diluted Shares Outstanding	11.59M	13.39M	39.09M	101.15M	112.84M	115.36M	119.17M	122.30M

This table shows 10x Genomics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-42	-17	-51	-62	-93	-49	-60	-38	-36	-49
Consolidated Net Income / (Loss)	-42	-17	-51	-62	-93	-49	-60	-38	-36	-49
Net Income / (Loss) Continuing Operations	-42	-17	-51	-62	-93	-49	-60	-38	-36	-49
Total Pre-Tax Income	-40	-16	-50	-61	-92	-47	-58	-37	-34	-48
Total Operating Income	-40	-23	-52	-63	-95	-55	-61	-42	-41	-50
Total Gross Profit	101	119	98	100	96	116	93	104	106	111
Total Revenue	131	156	134	147	154	184	141	153	152	165
Operating Revenue	131	156	134	147	154	184	141	153	152	165
Total Cost of Revenue	30	37	36	47	58	68	48	49	45	54
Operating Cost of Revenue	30	37	36	47	58	68	48	49	45	54
Total Operating Expenses	141	143	150	163	190	171	154	146	148	161
Selling, General & Admin Expense	73	79	83	92	82	86	86	83	82	94
Research & Development Expense	67	64	67	71	108	85	69	63	66	67
Total Other Income / (Expense), net	-0.04	6.29	2.33	2.59	3.05	8.59	3.70	4.66	7.05	1.46
Interest & Investment Income	2.03	2.82	3.87	4.10	4.30	4.64	4.74	4.72	4.97	4.03
Other Income / (Expense), net	-1.95	-	-1.52	-1.50	-1.25	3.96	-1.04	-0.06	2.08	-2.57
Income Tax Expense	1.88	0.80	1.09	1.65	1.24	2.35	2.15	0.82	1.32	0.65
Basic Earnings per Share	($0.37)	($0.14)	($0.44)	($0.53)	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)
Weighted Average Basic Shares Outstanding	114.11M	113.86M	115.62M	116.71M	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M
Diluted Earnings per Share	($0.37)	($0.14)	($0.44)	($0.53)	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)
Weighted Average Diluted Shares Outstanding	114.11M	113.86M	115.62M	116.71M	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M
Weighted Average Basic & Diluted Shares Outstanding	114.46M	115.36M	116.19M	117.42M	118.21M	119.17M	119.71M	120.49M	121.05M	122.30M

This table details how cash moves in and out of 10x Genomics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	6.11	22	406	212	-93	-369	132	-15
Net Cash From Operating Activities	-11	-76	35	-218	-21	-34	-15	6.66
Net Cash From Continuing Operating Activities	-11	-76	35	-218	-21	-34	-15	6.66
Net Income / (Loss) Continuing Operations	-19	-112	-31	-543	-58	-166	-255	-183
Consolidated Net Income / (Loss)	-19	-112	-31	-543	-58	-166	-255	-183
Depreciation Expense	4.31	3.91	7.07	14	21	25	36	36
Amortization Expense	0.15	0.46	0.10	5.03	7.14	7.64	8.11	7.83
Non-Cash Adjustments To Reconcile Net Income	1.66	3.70	14	356	96	137	179	144
Changes in Operating Assets and Liabilities, net	1.95	28	45	-50	-87	-37	18	1.78
Net Cash From Investing Activities	-3.76	-6.71	-43	-38	-107	-351	133	-33
Net Cash From Continuing Investing Activities	-3.76	-6.71	-43	-38	-107	-351	133	-33
Purchase of Property, Plant & Equipment	-3.76	-6.28	-43	-37	-101	-132	-49	-12
Acquisitions	0.00	-0.43	-0.03	-1.73	-5.45	-4.00	-0.92	-1.00
Purchase of Investments	-	-	-	0.00	0.00	-283	0.00	-49
Sale and/or Maturity of Investments	-	-	-	0.00	0.00	68	183	30
Net Cash From Financing Activities	21	105	415	469	35	16	14	11
Net Cash From Continuing Financing Activities	21	105	415	469	35	16	14	11
Repayment of Debt	0.00	-0.70	-11	-37	-5.03	-5.41	-5.81	0.00
Issuance of Common Equity	0.00	0.00	411	482	40	21	19	11
Effect of Exchange Rate Changes	-0.01	-0.02	-0.05	-0.46	0.23	-0.04	-0.03	-0.16
Cash Interest Paid	0.66	1.82	2.25	1.67	1.22	0.84	0.44	0.00
Cash Income Taxes Paid	0.00	0.01	0.02	0.28	8.66	3.93	4.93	5.64

This table details how cash moves in and out of 10x Genomics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-40	-14	112	-8.94	-16	45	-3.50	24	18	-54
Net Cash From Operating Activities	-9.56	14	-4.13	-12	-25	26	-16	7.50	22	-6.75
Net Cash From Continuing Operating Activities	-9.56	14	-4.13	-12	-25	26	-16	7.50	22	-6.75
Net Income / (Loss) Continuing Operations	-42	-17	-51	-62	-93	-49	-60	-38	-36	-49
Consolidated Net Income / (Loss)	-42	-17	-51	-62	-93	-49	-60	-38	-36	-49
Depreciation Expense	6.16	6.52	6.48	9.94	9.37	9.72	9.19	8.97	8.96	8.75
Amortization Expense	1.96	1.95	2.13	1.94	2.05	1.99	2.30	1.93	1.79	1.81
Non-Cash Adjustments To Reconcile Net Income	34	41	44	48	40	46	39	38	34	33
Changes in Operating Assets and Liabilities, net	-9.28	-19	-5.81	-9.47	16	17	-5.85	-4.00	13	-1.42
Net Cash From Investing Activities	-33	-33	120	-4.46	4.90	13	11	12	-3.62	-52
Net Cash From Continuing Investing Activities	-33	-33	120	-4.46	4.90	13	11	12	-3.62	-52
Purchase of Property, Plant & Equipment	-37	-40	-4.56	-25	-15	-3.45	-2.91	-2.88	-3.89	-2.72
Net Cash From Financing Activities	2.04	5.00	-3.41	7.10	4.37	5.61	1.64	4.60	0.16	4.52
Net Cash From Continuing Financing Activities	2.04	5.00	-3.41	7.10	4.37	5.61	1.64	4.60	0.16	4.52
Issuance of Common Equity	2.04	5.00	2.40	7.10	4.37	5.61	1.64	4.60	0.16	4.52
Effect of Exchange Rate Changes	-0.09	0.25	0.02	-0.05	-0.09	0.08	-0.05	-0.00	0.16	-0.27
Cash Income Taxes Paid	0.33	0.28	2.55	1.31	0.60	0.48	0.96	1.08	2.82	0.78

This table presents 10x Genomics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2018	2019	2020	2021	2022	2023	2024
Total Assets	124	606	929	1,019	1,029	965	919
Total Current Assets	106	481	774	748	635	596	584
Cash & Equivalents	65	424	664	587	220	359	344
Short-Term Investments	-	-	-	0.00	210	29	49
Accounts Receivable	28	33	51	85	104	115	88
Inventories, net	8.57	15	30	60	82	74	83
Prepaid Expenses	4.50	8.03	13	14	17	19	20
Plant, Property, & Equipment, net	11	49	73	169	289	280	253
Total Noncurrent Assets	6.95	76	82	102	105	90	82
Goodwill	-	-	0.00	4.51	4.51	4.51	4.51
Intangible Assets	-	-	22	25	23	17	16
Other Noncurrent Operating Assets	6.95	76	60	72	77	68	61
Total Liabilities & Shareholders' Equity	124	606	929	1,019	1,029	965	919
Total Liabilities	101	186	190	201	223	224	209
Total Current Liabilities	32	63	118	110	131	127	118
Accounts Payable	8.79	13	4.71	17	22	16	13
Accrued Expenses	9.94	24	43	51	60	57	41
Current Deferred Revenue	2.40	3.30	4.47	5.34	7.87	13	21
Current Employee Benefit Liabilities	7.05	12	15	32	33	30	34
Other Current Liabilities	-	0.00	50	5.13	9.04	12	9.29
Total Noncurrent Liabilities	69	123	72	91	92	97	91
Noncurrent Deferred Revenue	4.43	16	-	-	3.17	8.81	13
Other Noncurrent Operating Liabilities	39	87	72	91	89	88	78
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-220	420	739	818	806	741	710
Total Preferred & Common Equity	-220	420	739	818	806	741	710
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-220	420	739	818	806	741	710
Common Stock	11	682	1,544	1,681	1,839	2,026	2,178
Retained Earnings	-231	-262	-805	-863	-1,029	-1,284	-1,467
Accumulated Other Comprehensive Income / (Loss)	-0.04	-0.05	-0.05	0.02	-4.34	-0.43	-0.49

This table presents 10x Genomics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	996	1,014	990	949	923	930	938
Total Current Assets	629	602	583	562	567	579	594
Cash & Equivalents	234	332	326	311	356	380	398
Short-Term Investments	218	86	66	46	16	0.27	0.00
Accounts Receivable	84	78	88	104	91	91	84
Inventories, net	79	82	84	81	83	88	94
Prepaid Expenses	14	21	19	20	21	20	18
Plant, Property, & Equipment, net	258	292	285	285	269	263	259
Total Noncurrent Assets	109	120	122	101	86	87	85
Goodwill	4.51	4.51	4.51	4.51	4.51	4.51	4.51
Intangible Assets	23	23	22	22	16	17	16
Other Noncurrent Operating Assets	81	93	95	75	66	66	64
Total Liabilities & Shareholders' Equity	996	1,014	990	949	923	930	938
Total Liabilities	220	212	196	203	204	206	215
Total Current Liabilities	127	112	98	105	109	111	121
Accounts Payable	22	29	23	19	20	21	26
Accrued Expenses	62	47	34	36	42	42	38
Current Deferred Revenue	6.67	8.53	9.22	11	14	16	18
Current Employee Benefit Liabilities	28	18	22	28	21	20	30
Other Current Liabilities	8.39	9.20	9.29	10	11	11	9.42
Total Noncurrent Liabilities	94	100	98	99	95	95	94
Noncurrent Deferred Revenue	-	-	-	-	9.79	11	12
Other Noncurrent Operating Liabilities	94	100	98	99	86	83	81
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	776	802	793	745	719	724	723
Total Preferred & Common Equity	776	802	793	745	719	724	723
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	776	802	793	745	719	724	723
Common Stock	1,793	1,884	1,937	1,981	2,064	2,107	2,141
Retained Earnings	-1,012	-1,080	-1,142	-1,235	-1,344	-1,382	-1,418
Accumulated Other Comprehensive Income / (Loss)	-5.49	-1.48	-0.97	-0.68	-0.46	-0.43	0.03

This table displays calculated financial ratios and metrics derived from 10x Genomics' official financial filings.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	105.83%	68.06%	21.53%	64.13%	5.28%	19.81%	-1.28%
EBITDA Growth	0.00%	-673.74%	77.88%	-2,077.72%	95.17%	-444.88%	-64.29%	31.34%
EBIT Growth	0.00%	-508.69%	72.29%	-1,632.19%	90.04%	-216.92%	-57.98%	26.16%
NOPAT Growth	0.00%	-502.80%	72.40%	-1,647.10%	90.22%	-221.41%	-57.99%	26.67%
Net Income Growth	0.00%	-499.54%	72.22%	-1,636.68%	89.27%	-185.11%	-53.67%	28.41%
EPS Growth	0.00%	-418.52%	90.48%	-571.25%	90.13%	-175.47%	-49.32%	30.28%
Operating Cash Flow Growth	0.00%	-614.17%	145.32%	-729.27%	90.19%	-57.24%	54.78%	143.85%
Free Cash Flow Firm Growth	0.00%	0.00%	9.49%	-587.96%	49.22%	-26.52%	36.94%	39.03%
Invested Capital Growth	0.00%	0.00%	311.05%	129.76%	288.94%	62.87%	-5.57%	-10.11%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	14.10%	6.82%	2.52%	4.70%	-3.01%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-343.69%	94.08%	-4.90%	-15.12%	-1.55%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-302.75%	88.09%	-4.65%	-13.89%	-0.60%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-302.70%	88.28%	-4.52%	-13.76%	2.68%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-304.14%	87.21%	0.74%	-14.21%	-0.04%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-571.25%	88.09%	2.01%	-14.74%	1.30%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	250.08%	-168.93%	86.42%	19.07%	44.19%	-82.99%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	59.86%	-11.02%	27.71%	-31.01%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	1,973.47%	14.69%	15.56%	-9.14%	-2.44%
Profitability Metrics	-	-	-	-	-	-	-	-
Gross Margin	85.14%	80.41%	75.18%	80.44%	84.89%	76.69%	66.15%	67.86%
EBITDA Margin	-19.39%	-72.89%	-9.59%	-171.92%	-5.06%	-26.17%	-35.88%	-24.96%
Operating Margin	-25.85%	-75.70%	-12.43%	-178.74%	-10.65%	-32.52%	-42.88%	-31.85%
EBIT Margin	-25.66%	-75.87%	-12.51%	-178.29%	-10.82%	-32.56%	-42.93%	-32.11%
Profit (Net Income) Margin	-26.39%	-76.88%	-12.71%	-181.61%	-11.87%	-32.15%	-41.23%	-29.90%
Tax Burden Percent	100.11%	100.08%	100.70%	101.54%	108.39%	102.49%	102.55%	102.77%
Interest Burden Percent	102.76%	101.25%	100.89%	100.31%	101.24%	96.33%	93.65%	90.60%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	-317.31%	-884.57%	-25.40%	-39.04%	-51.20%	-40.71%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-312.73%	-853.15%	-21.99%	-29.55%	-34.31%	-28.84%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	303.21%	790.93%	17.92%	18.59%	18.22%	15.54%
Return on Equity (ROE)	0.00%	-483.66%	-14.10%	-93.64%	-7.48%	-20.45%	-32.98%	-25.17%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-230.86%	-963.27%	-143.59%	-86.88%	-45.47%	-30.06%
Operating Return on Assets (OROA)	0.00%	-89.30%	-8.42%	-69.41%	-5.45%	-16.42%	-26.64%	-20.82%
Return on Assets (ROA)	0.00%	-90.49%	-8.56%	-70.70%	-5.98%	-16.21%	-25.59%	-19.39%
Return on Common Equity (ROCE)	0.00%	4,574.93%	-6.36%	-93.64%	-7.48%	-20.45%	-32.98%	-25.17%
Return on Equity Simple (ROE_SIMPLE)	0.00%	51.13%	-7.44%	-73.43%	-7.12%	-20.60%	-34.42%	-25.72%
Net Operating Profit after Tax (NOPAT)	-13	-78	-21	-374	-37	-118	-186	-136
NOPAT Margin	-18.09%	-52.99%	-8.70%	-125.11%	-7.46%	-22.77%	-30.02%	-22.30%
Net Nonoperating Expense Percent (NNEP)	0.00%	-197.44%	-4.58%	-31.42%	-3.41%	-9.49%	-16.89%	-11.87%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-14.59%	-25.06%	-19.18%
Cost of Revenue to Revenue	14.86%	19.59%	24.82%	19.56%	15.11%	23.31%	33.85%	32.14%
SG&A Expenses to Revenue	65.75%	60.10%	53.21%	67.70%	52.51%	57.76%	55.49%	56.38%
R&D to Revenue	45.25%	75.11%	33.79%	191.04%	43.17%	51.45%	53.55%	43.34%
Operating Expenses to Revenue	110.99%	156.11%	87.61%	259.17%	95.55%	109.21%	109.04%	99.71%
Earnings before Interest and Taxes (EBIT)	-18	-111	-31	-533	-53	-168	-266	-196
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-14	-107	-24	-514	-25	-135	-222	-152
Valuation Ratios	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	17.46	20.62	20.35	5.18	8.93	2.45
Price to Tangible Book Value (P/TBV)	0.00	0.00	17.46	21.26	21.13	5.36	9.19	2.52
Price to Revenue (P/Rev)	5.49	2.67	29.82	50.99	33.93	8.08	10.69	2.85
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	270.66	247.14	70.07	10.02	17.67	4.25
Enterprise Value to Revenue (EV/Rev)	0.00	4.09	28.22	48.71	32.73	7.24	10.06	2.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	200.38	0.00	0.00	0.00	0.00	201.82
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-
Debt to Equity	0.00	1.28	0.07	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	1.10	0.05	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.52	-0.97	-0.93	-0.82	-0.63	-0.53	-0.54
Leverage Ratio	0.00	5.35	1.65	1.32	1.25	1.26	1.29	1.30
Compound Leverage Factor	0.00	5.41	1.66	1.33	1.27	1.22	1.21	1.18
Debt to Total Capital	0.00%	56.06%	6.61%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	7.91%	2.20%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	48.15%	4.41%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	459.53%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-415.60%	93.39%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	-0.28	-1.26	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.33	16.72	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.24	-0.84	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	-0.38	-1.39	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.46	18.43	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.33	-0.93	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	-1.34	24.13	46.11	49.48	10.36	16.16	3.34
Noncontrolling Interest Sharing Ratio	0.00%	1,045.90%	54.87%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-
Current Ratio	0.00	3.28	7.63	6.56	6.77	4.85	4.69	4.97
Quick Ratio	0.00	2.88	7.26	6.05	6.10	4.08	3.96	4.09
Cash Flow Metrics	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-65	-59	-407	-207	-262	-165	-101
Operating Cash Flow to CapEx	-284.85%	-1,215.93%	81.01%	-594.28%	-21.10%	-25.52%	-31.27%	53.77%
Free Cash Flow to Firm to Interest Expense	0.00	-27.14	-19.22	-242.07	-238.76	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-13.19	-31.72	11.25	-129.55	-24.68	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-17.82	-34.33	-2.64	-151.35	-141.63	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-
Asset Turnover	0.00	1.18	0.67	0.39	0.50	0.50	0.62	0.65
Accounts Receivable Turnover	0.00	5.21	8.00	7.07	7.19	5.45	5.65	6.03
Inventory Turnover	0.00	3.34	5.12	2.59	1.65	1.70	2.70	2.50
Fixed Asset Turnover	0.00	13.15	8.20	4.91	4.05	2.25	2.18	2.30
Accounts Payable Turnover	0.00	3.26	5.59	6.59	6.72	6.18	11.22	13.71
Days Sales Outstanding (DSO)	0.00	70.07	45.61	51.65	50.77	66.96	64.61	60.56
Days Inventory Outstanding (DIO)	0.00	109.14	71.29	141.18	221.50	214.65	135.37	145.79
Days Payable Outstanding (DPO)	0.00	111.97	65.25	55.36	54.34	59.05	32.54	26.63
Cash Conversion Cycle (CCC)	0.00	67.24	51.65	137.46	217.94	222.56	167.44	179.72
Capital & Investment Metrics	-	-	-	-	-	-	-	-
Invested Capital	0.00	-12	26	59	229	373	352	317
Invested Capital Turnover	0.00	-24.09	36.46	7.07	3.41	1.72	1.71	1.83
Increase / (Decrease) in Invested Capital	0.00	-12	38	33	170	144	-21	-36
Enterprise Value (EV)	0.00	598	6,939	14,557	16,051	3,738	6,226	1,345
Market Capitalization	390	390	7,333	15,237	16,640	4,171	6,615	1,738
Book Value per Share	$0.00	($16.43)	$4.37	$6.87	$7.32	$7.04	$6.27	$5.87
Tangible Book Value per Share	$0.00	($16.43)	$4.37	$6.66	$7.05	$6.80	$6.09	$5.70
Total Capital	0.00	53	450	739	818	806	741	710
Total Debt	0.00	30	30	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	25	20	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-35	-394	-680	-588	-433	-389	-393
Capital Expenditures (CapEx)	3.76	6.28	43	37	101	132	49	12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	13	3.51	-24	49	71	80	73
Debt-free Net Working Capital (DFNWC)	0.00	78	428	656	637	504	469	467
Net Working Capital (NWC)	0.00	74	418	656	637	504	469	467
Net Nonoperating Expense (NNE)	5.90	35	9.85	169	22	48	69	46
Net Nonoperating Obligations (NNO)	0.00	-35	-394	-680	-588	-433	-389	-393
Total Depreciation and Amortization (D&A)	4.45	4.36	7.17	19	28	33	44	44
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	8.87%	1.43%	-8.01%	9.94%	13.84%	12.96%	12.01%
Debt-free Net Working Capital to Revenue	0.00%	53.35%	173.93%	219.59%	129.92%	97.61%	75.78%	76.42%
Net Working Capital to Revenue	0.00%	50.49%	169.91%	219.59%	129.92%	97.61%	75.78%	76.42%
Earnings Adjustments	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	96.55M	108.75M	110.35M	113.86M	117.17M	120.45M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.80)	($5.37)	($0.53)	($1.46)	($2.18)	($1.52)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	96.55M	108.75M	110.35M	113.86M	117.17M	120.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.80)	($5.37)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	39.09M	101.15M	112.84M	115.36M	119.17M	122.30M
Normalized Net Operating Profit after Tax (NOPAT)	-13	-56	-20	-374	-37	-118	-186	-136
Normalized NOPAT Margin	-18.09%	-38.36%	-8.28%	-125.11%	-7.55%	-22.77%	-30.02%	-22.30%
Pre Tax Income Margin	-26.36%	-76.82%	-12.62%	-178.85%	-10.95%	-31.36%	-40.21%	-29.09%
Debt Service Ratios	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-22.49	-46.08	-9.99	-316.77	-61.26	0.00	0.00	0.00
NOPAT to Interest Expense	-15.86	-32.19	-6.95	-222.29	-42.24	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-27.12	-48.69	-23.87	-338.57	-178.21	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-20.49	-34.79	-20.83	-244.09	-159.19	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.43%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from 10x Genomics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	4.61%	8.85%	17.28%	28.10%	17.22%	17.76%	5.01%	4.28%	-1.30%	-10.30%
EBITDA Growth	-267.61%	-72.03%	-32.96%	6.25%	-150.13%	-170.25%	-13.71%	41.69%	66.14%	-5.87%
EBIT Growth	-154.56%	-45.95%	-28.20%	0.15%	-128.97%	-121.80%	-16.88%	35.57%	58.97%	-2.30%
NOPAT Growth	-151.88%	-45.90%	-24.57%	-0.38%	-137.01%	-138.95%	-18.29%	34.13%	56.24%	9.69%
Net Income Growth	-144.10%	6.69%	-19.65%	3.17%	-121.85%	-184.36%	-18.13%	39.28%	61.55%	-0.16%
EPS Growth	-146.67%	17.65%	-15.79%	7.02%	-113.51%	-200.00%	-13.64%	39.62%	62.03%	4.76%
Operating Cash Flow Growth	63.52%	136.40%	80.17%	32.05%	-164.58%	87.70%	-281.21%	165.04%	185.52%	-126.20%
Free Cash Flow Firm Growth	29.38%	11.62%	16.05%	11.74%	13.15%	88.86%	94.38%	116.86%	126.00%	104.08%
Invested Capital Growth	61.65%	62.87%	42.74%	41.35%	20.10%	-5.57%	-9.06%	-14.10%	-16.29%	-10.11%
Revenue Q/Q Growth	14.36%	19.20%	-14.05%	9.33%	4.65%	19.74%	-23.36%	8.58%	-0.95%	8.81%
EBITDA Q/Q Growth	40.14%	56.77%	-206.95%	-18.04%	-59.71%	53.30%	-29.16%	39.48%	7.24%	-46.01%
EBIT Q/Q Growth	35.43%	44.94%	-131.66%	-21.23%	-48.07%	46.66%	-22.08%	33.17%	5.71%	-32.99%
NOPAT Q/Q Growth	36.63%	42.25%	-125.10%	-21.87%	-49.62%	41.78%	-11.43%	32.13%	0.60%	-20.14%
Net Income Q/Q Growth	34.97%	58.93%	-194.78%	-22.99%	-48.98%	47.36%	-22.46%	36.78%	5.66%	-37.13%
EPS Q/Q Growth	35.09%	62.16%	-214.29%	-20.45%	-49.06%	46.84%	-19.05%	36.00%	6.25%	-33.33%
Operating Cash Flow Q/Q Growth	43.62%	243.49%	-130.06%	-179.42%	-119.54%	201.79%	-161.05%	147.67%	188.70%	-131.18%
Free Cash Flow Firm Q/Q Growth	17.40%	-5.99%	5.96%	-7.20%	18.72%	86.40%	52.54%	421.41%	25.30%	-97.86%
Invested Capital Q/Q Growth	13.99%	15.56%	2.27%	4.93%	-3.15%	-9.14%	-1.51%	-0.88%	-5.62%	-2.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	76.82%	76.43%	73.27%	67.85%	62.18%	62.93%	65.89%	68.07%	70.16%	67.24%
EBITDA Margin	-25.81%	-9.36%	-33.43%	-36.09%	-55.08%	-21.48%	-36.20%	-20.18%	-18.90%	-25.36%
Operating Margin	-30.51%	-14.78%	-38.71%	-43.15%	-61.70%	-30.00%	-43.61%	-27.26%	-27.36%	-30.20%
EBIT Margin	-32.00%	-14.78%	-39.84%	-44.18%	-62.51%	-27.84%	-44.35%	-27.30%	-25.98%	-31.76%
Profit (Net Income) Margin	-31.98%	-11.02%	-37.79%	-42.51%	-60.52%	-26.61%	-42.52%	-24.75%	-23.58%	-29.71%
Tax Burden Percent	104.69%	104.90%	102.20%	102.71%	101.35%	105.05%	103.71%	102.21%	103.82%	101.34%
Interest Burden Percent	95.44%	71.06%	92.80%	93.69%	95.52%	90.96%	92.43%	88.72%	87.39%	92.32%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-41.17%	-17.75%	-44.78%	-50.23%	-71.83%	-35.82%	-52.41%	-32.39%	-33.85%	-38.60%
ROIC Less NNEP Spread (ROIC-NNEP)	-38.53%	-17.54%	-41.79%	-46.18%	-65.25%	-33.30%	-48.15%	-30.14%	-32.07%	-34.98%
Return on Net Nonoperating Assets (RNNOA)	25.75%	11.03%	24.94%	26.16%	34.76%	17.68%	25.09%	15.36%	16.51%	18.85%
Return on Equity (ROE)	-15.42%	-6.71%	-19.85%	-24.07%	-37.06%	-18.13%	-27.33%	-17.03%	-17.34%	-19.75%
Cash Return on Invested Capital (CROIC)	-90.16%	-86.88%	-73.66%	-70.81%	-64.21%	-45.47%	-43.32%	-32.46%	-21.55%	-30.06%
Operating Return on Assets (OROA)	-16.23%	-7.46%	-21.18%	-25.22%	-37.99%	-17.28%	-28.64%	-17.97%	-17.35%	-20.59%
Return on Assets (ROA)	-16.21%	-5.56%	-20.09%	-24.27%	-36.78%	-16.51%	-27.46%	-16.29%	-15.74%	-19.27%
Return on Common Equity (ROCE)	-15.42%	-6.71%	-19.85%	-24.07%	-37.06%	-18.13%	-27.33%	-17.03%	-17.34%	-19.75%
Return on Equity Simple (ROE_SIMPLE)	-21.56%	0.00%	-21.73%	-21.72%	-29.97%	0.00%	-36.77%	-33.12%	-25.26%	0.00%
Net Operating Profit after Tax (NOPAT)	-28	-16	-36	-44	-66	-39	-43	-29	-29	-35
NOPAT Margin	-21.36%	-10.35%	-27.10%	-30.21%	-43.19%	-21.00%	-30.53%	-19.08%	-19.15%	-21.14%
Net Nonoperating Expense Percent (NNEP)	-2.64%	-0.21%	-2.99%	-4.05%	-6.57%	-2.51%	-4.26%	-2.25%	-1.78%	-3.62%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.01%	-	-	-	-5.21%	-	-	-	-4.91%
Cost of Revenue to Revenue	23.18%	23.57%	26.73%	32.15%	37.82%	37.07%	34.11%	31.93%	29.84%	32.76%
SG&A Expenses to Revenue	56.00%	50.49%	62.02%	62.33%	53.64%	46.81%	60.83%	54.24%	53.88%	56.86%
R&D to Revenue	51.34%	40.72%	49.97%	48.67%	70.23%	46.12%	48.68%	41.09%	43.63%	40.58%
Operating Expenses to Revenue	107.34%	91.21%	111.98%	111.00%	123.87%	92.93%	109.51%	95.33%	97.51%	97.44%
Earnings before Interest and Taxes (EBIT)	-42	-23	-54	-65	-96	-51	-63	-42	-39	-52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-34	-15	-45	-53	-85	-40	-51	-31	-29	-42
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.18	5.18	8.02	8.18	6.50	8.93	6.17	3.22	3.76	2.45
Price to Tangible Book Value (P/TBV)	4.34	5.36	8.31	8.46	6.74	9.19	6.35	3.31	3.87	2.52
Price to Revenue (P/Rev)	6.44	8.08	12.00	11.41	8.20	10.69	7.09	3.69	4.32	2.85
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.64	10.02	15.76	15.22	11.57	17.67	11.71	5.66	7.15	4.25
Enterprise Value to Revenue (EV/Rev)	5.54	7.24	11.22	10.72	7.59	10.06	6.50	3.08	3.69	2.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	59.29	201.82
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.67	-0.63	-0.60	-0.57	-0.53	-0.53	-0.52	-0.51	-0.51	-0.54
Leverage Ratio	1.26	1.26	1.25	1.26	1.28	1.29	1.27	1.26	1.29	1.30
Compound Leverage Factor	1.20	0.90	1.16	1.18	1.22	1.17	1.18	1.12	1.12	1.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.38	10.83	17.69	19.16	13.34	16.90	12.05	5.85	6.61	3.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.96	4.85	5.37	5.94	5.37	4.69	5.22	5.22	4.90	4.97
Quick Ratio	4.22	4.08	4.43	4.88	4.40	3.96	4.26	4.25	3.97	4.09
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-151	-160	-151	-161	-131	-18	-8.47	27	34	0.73
Operating Cash Flow to CapEx	-26.15%	34.54%	-90.48%	-45.46%	-166.08%	746.61%	-540.38%	260.46%	556.47%	-248.45%
Free Cash Flow to Firm to Interest Expense	-1,325.81	0.00	-7,929.03	0.00	0.00	0.00	-8,473.60	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-83.89	0.00	-217.11	0.00	0.00	0.00	-15,725.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-404.70	0.00	-457.05	0.00	0.00	0.00	-18,635.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.50	0.53	0.57	0.61	0.62	0.65	0.66	0.67	0.65
Accounts Receivable Turnover	6.22	5.45	6.94	6.94	6.31	5.65	7.39	7.06	6.72	6.03
Inventory Turnover	1.71	1.70	1.79	1.95	2.23	2.70	2.68	2.60	2.41	2.50
Fixed Asset Turnover	2.52	2.25	2.22	2.24	2.18	2.18	2.23	2.30	2.32	2.30
Accounts Payable Turnover	5.75	6.18	5.42	6.03	8.81	11.22	8.95	10.06	9.34	13.71
Days Sales Outstanding (DSO)	58.69	66.96	52.57	52.62	57.87	64.61	49.38	51.67	54.30	60.56
Days Inventory Outstanding (DIO)	213.06	214.65	203.71	187.39	163.54	135.37	136.29	140.55	151.74	145.79
Days Payable Outstanding (DPO)	63.43	59.05	67.35	60.53	41.44	32.54	40.79	36.27	39.07	26.63
Cash Conversion Cycle (CCC)	208.32	222.56	188.93	179.48	179.97	167.44	144.88	155.95	166.98	179.72
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	323	373	382	400	388	352	347	344	325	317
Invested Capital Turnover	1.93	1.72	1.65	1.66	1.66	1.71	1.72	1.70	1.77	1.83
Increase / (Decrease) in Invested Capital	123	144	114	117	65	-21	-35	-56	-63	-36
Enterprise Value (EV)	2,791	3,738	6,015	6,095	4,486	6,226	4,065	1,948	2,323	1,345
Market Capitalization	3,244	4,171	6,436	6,488	4,844	6,615	4,436	2,328	2,721	1,738
Book Value per Share	$6.81	$7.04	$6.96	$6.83	$6.35	$6.27	$6.02	$6.05	$6.00	$5.87
Tangible Book Value per Share	$6.56	$6.80	$6.72	$6.60	$6.12	$6.09	$5.85	$5.87	$5.83	$5.70
Total Capital	776	806	802	793	745	741	719	724	723	710
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-453	-433	-421	-393	-357	-389	-372	-380	-398	-393
Capital Expenditures (CapEx)	37	40	4.56	25	15	3.45	2.91	2.88	3.89	2.72
Debt-free, Cash-free Net Working Capital (DFCFNWC)	50	71	69	92	100	80	87	88	74	73
Debt-free Net Working Capital (DFNWC)	503	504	490	485	458	469	458	468	473	467
Net Working Capital (NWC)	503	504	490	485	458	469	458	468	473	467
Net Nonoperating Expense (NNE)	14	1.05	14	18	27	10	17	8.68	6.71	14
Net Nonoperating Obligations (NNO)	-453	-433	-421	-393	-357	-389	-372	-380	-398	-393
Total Depreciation and Amortization (D&A)	8.12	8.47	8.62	12	11	12	11	11	11	11
Debt-free, Cash-free Net Working Capital to Revenue	9.86%	13.84%	12.89%	16.18%	16.96%	12.96%	13.84%	13.94%	11.83%	12.01%
Debt-free Net Working Capital to Revenue	99.77%	97.61%	91.36%	85.30%	77.44%	75.78%	73.29%	74.10%	75.06%	76.42%
Net Working Capital to Revenue	99.77%	97.61%	91.36%	85.30%	77.44%	75.78%	73.29%	74.10%	75.06%	76.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.37)	($0.14)	($0.44)	($0.53)	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)
Adjusted Weighted Average Basic Shares Outstanding	114.11M	113.86M	115.62M	116.71M	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M
Adjusted Diluted Earnings per Share	($0.37)	($0.14)	($0.44)	($0.53)	($0.79)	($0.42)	($0.50)	($0.32)	($0.30)	($0.40)
Adjusted Weighted Average Diluted Shares Outstanding	114.11M	113.86M	115.62M	116.71M	117.73M	117.17M	119.39M	120.07M	120.73M	120.45M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	114.46M	115.36M	116.19M	117.42M	118.21M	119.17M	119.71M	120.49M	121.05M	122.30M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-16	-36	-44	-66	-39	-43	-29	-29	-35
Normalized NOPAT Margin	-21.36%	-10.35%	-27.10%	-30.21%	-43.19%	-21.00%	-30.53%	-19.08%	-19.15%	-21.14%
Pre Tax Income Margin	-30.54%	-10.50%	-36.98%	-41.39%	-59.71%	-25.33%	-40.99%	-24.22%	-22.71%	-29.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-367.95	0.00	-2,816.00	0.00	0.00	0.00	-62,538.00	0.00	0.00	0.00
NOPAT to Interest Expense	-245.59	0.00	-1,915.35	0.00	0.00	0.00	-43,048.60	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-688.75	0.00	-3,055.95	0.00	0.00	0.00	-65,448.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-566.40	0.00	-2,155.29	0.00	0.00	0.00	-45,958.60	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About 10x Genomics' Financials

When does 10x Genomics's financial year end?

According to the most recent income statement we have on file, 10x Genomics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has 10x Genomics' net income changed over the last 7 years?

10x Genomics' net income appears to be on an upward trend, with a most recent value of -$182.63 million in 2024, rising from -$18.76 million in 2017. The previous period was -$255.10 million in 2023.

What is 10x Genomics's operating income?

10x Genomics's total operating income in 2024 was -$194.56 million, based on the following breakdown:

Total Gross Profit: $414.48 million
Total Operating Expenses: $609.04 million

How has 10x Genomics revenue changed over the last 7 years?

Over the last 7 years, 10x Genomics' total revenue changed from $71.09 million in 2017 to $610.79 million in 2024, a change of 759.2%.

How much debt does 10x Genomics have?

10x Genomics' total liabilities were at $208.50 million at the end of 2024, a 7.0% decrease from 2023, and a 106.3% increase since 2018.

How much cash does 10x Genomics have?

In the past 6 years, 10x Genomics' cash and equivalents has ranged from $65.08 million in 2018 to $663.60 million in 2020, and is currently $344.07 million as of their latest financial filing in 2024.

How has 10x Genomics' book value per share changed over the last 7 years?

Over the last 7 years, 10x Genomics' book value per share changed from 0.00 in 2017 to 5.87 in 2024, a change of 586.6%.

Remove Ads

Related Companies

This page (NASDAQ:TXG) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Financials

Frequently Asked Questions About 10x Genomics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Financials

Annual Income Statements for 10x Genomics

Quarterly Income Statements for 10x Genomics

Annual Cash Flow Statements for 10x Genomics

Quarterly Cash Flow Statements for 10x Genomics

Annual Balance Sheets for 10x Genomics

Quarterly Balance Sheets for 10x Genomics

Annual Metrics and Ratios for 10x Genomics

Quarterly Metrics and Ratios for 10x Genomics

Frequently Asked Questions About 10x Genomics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools